Mizuho raised the firm’s price target on Corbus Pharmaceuticals (CRBP) to $39 from $32 and keeps an Outperform rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- Corbus Pharmaceuticals Advances CRB-701 Clinical Study for Solid Tumors
- Corbus Pharmaceuticals’ CRB-601 Study: A New Hope for Advanced Solid Tumors
- Corbus Pharmaceuticals Presents Promising CRB-701 Study Results
- Corbus Pharmaceuticals price target raised to $51 from $35 at Piper Sandler
- Promising Trial Results and Market Potential Drive Buy Rating for Corbus Pharmaceuticals’ CRB-701